In non-small-cell lung cancer (NSCLC) combined HDAC and mTOR inhibition resulted in a synergistic decrease of migration and invasion in vitro and diminished metastasis rates in vivo [72]. The gene discussed is HDAC9; the disease is non-small cell lung carcinoma.